The results of this study uncover a novel vulnerability of MSI-H tumor cell models and indicate that pharmacological inhibition of WRN ATPase/helicase function might serve as an attractive targeted therapeutic strategy in MSI-H cancer. The gene discussed is WRN; the disease is neoplasm.